Rigontec today announced the dosing of the first patient in a phase I/II study with intratumoral/intralesional administration of its lead compound RGT100 in solid tumors and lymphoma. In addition, Rigontec appoints industry veteran Prof. Eugen Leo as Chief Medical Officer.
by eazee-designstudio
